Vertex Pharmaceuticals VRTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 86.2%+0.2pp | 86.2%+0.1pp | 86.3%+0.2pp | 86.1%-0.3pp | 86%-0.8pp | |
| Operating margin | 38.3%— | 34.8%— | —— | —— | —— | |
| Net margin | 35.5%— | 32.9%— | —— | —— | —— | |
| EBITDA margin | 40.1%+43.9pp | 36.5%+35.7pp | 36.7%+37.2pp | 37.1%+38.5pp | -3.8%-46.9pp | |
| Free cash flow margin | 30.4%+61.4pp | 26.6%+53.6pp | 22.6%+47.1pp | 11.5%+22.9pp | -31%-67.5pp | |
| Returns | ||||||
| Return on equity | 24.2%— | 22.5%— | —— | —— | —— | |
| Return on assets | 17.6%— | 16.4%— | —— | —— | —— | |
| Return on invested capital | 26.8%+32.2pp | 24.3%+24.9pp | 25.7%+26.9pp | 27%+28.5pp | -5.3%-35.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Inventory turnover | 1.1×-0.4× | 1.1×-0.4× | 1.2×-0.5× | 1.3×-0.5× | 1.4×-0.6× | |
| Liquidity | ||||||
| Current ratio | 3×+0.4× | 2.9×+0.2× | 2.4×-0.1× | 2.5×0.0× | 2.6×-0.9× | |
| Quick ratio | 2.6×+0.3× | 2.5×+0.1× | 2×-0.2× | 2.2×-0.1× | 2.3×-1.0× | |
| Cash ratio | 1.4×+0.2× | 1.3×0.0× | 1.1×-0.2× | 1.2×-0.1× | 1.2×-1.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | -0.7×— | -0.7×+31.5× | -0.7×— | -0.8×— | —— | |
| Per Share | ||||||
| Book value per share | $75.54+18.8% | $72.35+13.7% | $67.23+12.3% | $66.34+15.9% | $63.57-10.5% | |
| Valuation | ||||||
| Market capitalization | $113.44B-8.9% | $115.03B+10.9% | $100.41B-16.3% | $115.63B-4.5% | $124.5B+15.3% | |
| Enterprise value | $109.92B-9.5% | $111.97B+11.0% | $97.3B-16.5% | $112.17B-4.4% | $121.46B+22.1% | |
| Price / earnings | 26.1×— | 29.1×— | —— | —— | —— | |
| Price / sales | 9.3×-1.9× | 9.6×+0.2× | 8.6×-2.7× | 10.1×-1.6× | 11.2×+0.6× | |
| Price / book | 5.9×-1.7× | 6.2×-0.2× | 5.8×-1.9× | 6.7×-1.5× | 7.5×+1.7× | |
| EV / EBITDA | 22.4×— | 25.5×-1,126× | 22.6×— | 26.5×— | —— | |
| EV / sales | 9×-1.9× | 9.3×+0.2× | 8.3×-2.7× | 9.8×-1.5× | 10.9×+1.2× | |
| Free cash flow yield | 3.3%+6.0pp | 2.8%+5.6pp | 2.6%+4.8pp | 1.1%+2.1pp | -2.8%-6.2pp | |
| Earnings yield | 3.8%— | 3.4%— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vertex Pharmaceuticals's profit margins?
- Vertex Pharmaceuticals (VRTX) runs a 86.2% gross margin and a 38.3% operating margin, with a 35.5% net margin.
- Where do Vertex Pharmaceuticals's ratios come from?
- Every ratio is computed from Vertex Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
